miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
July 28, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
FRANKFURT, Germany and BOULDER, Colo., July 28, 2020 (GLOBE NEWSWIRE) -- Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage...
Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
July 23, 2020 16:32 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020
July 22, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., July 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Regains Compliance With Nasdaq Listing Requirements
July 02, 2020 16:15 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., July 02, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis
June 22, 2020 17:08 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., June 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer
June 18, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
June 16, 2020 16:01 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference
May 26, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 07, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020Additional NIH grant funding released in...
miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020
April 23, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., April 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...